CN105954519A - Kit for specific detection on oral cancer - Google Patents

Kit for specific detection on oral cancer Download PDF

Info

Publication number
CN105954519A
CN105954519A CN201610505457.7A CN201610505457A CN105954519A CN 105954519 A CN105954519 A CN 105954519A CN 201610505457 A CN201610505457 A CN 201610505457A CN 105954519 A CN105954519 A CN 105954519A
Authority
CN
China
Prior art keywords
bpifb2
aptamer
oral cancer
dna
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610505457.7A
Other languages
Chinese (zh)
Inventor
陈博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610505457.7A priority Critical patent/CN105954519A/en
Publication of CN105954519A publication Critical patent/CN105954519A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4743—Bactericidal/Permeability-increasing protein BPI

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a kit for specific detection on oral cancer. The aptamer provided by the invention has relatively good affinity with human BPIFB2 protein. By adoption of the aptamer provided by the invention, the BPIFB2 protein in saliva can be captured, oral cancer can be detected according to content change of the BPIFB2 protein, and thus a corresponding kit for screening oral cancer can be prepared from the aptamer. The kit disclosed by the invention has the beneficial effects of high sensitivity and low cost.

Description

A kind of test kit of oral cancer specific detection
The application is filing date November 15, Application No. 201510775735.6, invention name in 2015 It is referred to as the divisional application of the application for a patent for invention of " test kit of a kind of oral cancer specific detection ".
Technical field
The present invention relates to a kind of test kit for detecting oral cancer and detection method thereof.
Background technology
Oral cancer (Oral Squarmous Cell Carcinomas, 0SCC) is one of common tumor of human body, Especially can reach whole tumor at its sickness rate such as India of developing country, Sri Lanka, Brazil 25%.The sickness rate of oral cancer has obvious ascendant trend in developed countries such as America and Europes in recent years, particularly falls ill Age tends to rejuvenation.Oral squamous cell carcinomas not only sickness rate is high, and grade malignancy is higher；Often result in voice, Chew, swallow, the dysfunction such as face and serious face are damaged, and threaten the life of patient；Life in 5 years The rate of depositing only has about 60%.Although recently oral cancer operation method update with radiotherapy, chemotherapy extensive Application, but the five year survival rate of oral cancer is not significantly improved.Cause main reason is that of this situation: The pathogenesis of oral cancer is unclear, and Invasion and Metastasis mechanism is failed to understand, lacks effective early prevention and Index for diagnosis Means.Therefore research oral cancer occurs and the molecular mechanism of development, therefrom finds oral cancer early prevention, pre- Rear judgement and Therapeutic Method are significant problems anxious to be resolved in oral cancer research.
BPIFB2 gene known in the art has good phase with the relation of oral cancer: BPIFB2 with oral cancer Guan Xing, can be used for preparing oral cancer auxiliary diagnosis or prognosis preparation, has important clinical value.Its Middle BPIFB2 expression in cancer beside organism is significantly lower than oral cancer tumor tissue and control plasmid OOcopies, and the BPIFB2 high expressed in oral cancer tissue, i.e. bioinformatics screening obtain BPIFB2 gene and oral cancer have good dependency, can be used for preparing oral cancer auxiliary diagnosis or prognosis Preparation.Therefore the expression detecting BPIFB2 becomes particularly important.
Aptamer (Aptamer, also known as aptamers, aptamer) is can high-affinity, the combination of high specific Certain biological leather El target strand widow's nucleic acid molecules (ssDNA or ssRNA).Aptamer is rich by index Collection Fas lignand system evolution technology (Systemat1c Evolut1on of L1gands by Exponent1al Enr1chment, SELEX) from the DNA/RNA library of synthetic screening obtain can high degree of specificity knot Close the single stranded DNA/RNA of target molecules.Reported the target of aptamer include metal ion, organic molecule, Polypeptide, protein, cell even tissue etc..The molecular recognition function of aptamer is similar with antibody, have with The target identification ability that antibody molecule is the most higher, but there is compared with antibody the most excellent characteristic, as Molecular weight is little, can manufacture, not easy in inactivation, non-immunogenicity, be readily synthesized with labelling, quickly penetrate Between tissue, good dynamic metabolism, different batches, product does not haves difference and has fine chemically stable Property, in fields such as biological detection, medical diagnosis on disease treatments, there is important application prospect.
Summary of the invention
It is an object of the invention to provide aptamer and the test kit thereof of a kind of specific bond BPIFB2.
The aptamer that the present invention provides, is the single stranded DNA shown in sequence 1-15 of sequence table.
Described aptamer and BPIFB2 albumen have preferable affinity.
Also described aptamer can be modified or transformed, obtain the derivant of described aptamer.
The derivant of described aptamer can be following any one:
A) described aptamer being deleted part or increases the nucleotide of partial complementarity, obtain fits with described nucleic acid Body has the derivant of the aptamer of identical function；
B) described aptamer carrying out nucleotide replacement or part is modified, obtain has with described aptamer The derivant of the aptamer of identical function；
C) transforming the skeleton of described aptamer as phosphorothioate backbone, obtain has with described aptamer There is the derivant of the aptamer of identical function；
D) aptamer is transform peptide nucleic acid(PNA) as, obtain with described aptamer have identical function nucleic acid fit The derivant of body；
E) after described aptamer being connected upper fluorescence, radioactivity and therapeutic substance, that obtain with described nucleic acid The derivant of the fit aptamer with identical function.
Described aptamer can be used for the test kit of preparation detection BPIFB2.
Utilize the aptamer of the present invention, in can capturing in saliva in BPIFB2, thus be used for being correlated with Oral cancer examination.Utilize the aptamer of the present invention, have highly sensitive, low cost, easily preparation, easily preservation Advantage.The present invention has the highest using value.
Detailed description of the invention
Below example facilitates a better understanding of the present invention, but does not limit the present invention.In following embodiment Experimental technique, if no special instructions, is conventional method.
The acquisition of embodiment 1 BPIFB2 albumen
BPIFB2 gene shown in NP_079503 is expressed by the eukaryotic expression mode that this area is conventional, Obtain corresponding desired polypeptides albumen.
The screening of embodiment 2 aptamer and preparation
Two ends comprise about 20 nucleotide, centre includes that the random nucleic acid library of 41 nucleotide is as follows in design:
5‘-ACCTGATGCCATGCATCGCA(N41)CTAGCCAGCCTTTGACATCA-3’；N41 represents 41 Individual random nucleotide.
Being double-stranded DNA by single-stranded DNA banks amplification, product is through 2% agarose gel electrophoresis and cuts glue recovery purification； With reclaim double-stranded DNA as template, in vitro transcription goes out single stranded RNA random library, and transcription product is pure through PAGE Change.The RNA molecule being combined with film is removed, then with 2ug through anti-sieve of nitrocellulose filter in 75 μ g RNA libraries BPIFB2 albumen, hatches 30min for 37 DEG C, and reactant liquor filters through nitrocellulose filter, washs filter membrane；Then Filter membrane is shredded, be placed in elution buffer (6mol/L carbamide, 0.55mol/L ammonium acetate, l.5mmol/L EDTA, 0.15%SDS) in boil 5min, centrifugal, take supernatant, dehydrated alcohol precipitation RNA, and again dissolve In 20 μ 1DEPC water；With RNA for template RT-PCR amplifying doulbe-chain DNA, in vitro transcription goes out RNA literary composition Storehouse is screened for next round；Often in wheel screening process, RT-PCR obtains double-stranded DNA library, with this double-stranded DNA Going out RNA aptamer storehouse for template in vitro transcription, screening carries out 11 altogether and takes turns.16 aptamers, its sequence are obtained Row are respectively shown in SEQ ID NO:1-16.Particular sequence is as follows:
BPIFB2-1:
ACCTGATGCCATGCATCGCATCACACGATCATCACACCGCTCCGCCTTCCAACTACCGCTC CTAGCCAGCCTTTGACATCA
BPIFB2-2:
ACCTGATGCCATGCATCGCACACCTCCACCCTTCGCAACTACCTCTCTTCCTGTAACTATT CTAGCCAGCCTTTGACATCA
BPIFB2-3:
ACCTGATGCCATGCATCGCATCTCATAACAAATCTTCATAATCTTCTATAACACTGTCAAT CTAGCCAGCCTTTGACATCA
BPIFB2-4:
ACCTGATGCCATGCATCGCACATCTATATAGAATATATTCAATCCTCTCTCTTATATGCAT CTAGCCAGCCTTTGACATCA
BPIFB2-5:
ACCTGATGCCATGCATCGCACTATCAACGACTCTCACGCAACGCTCTTCTTACTACATATA CTAGCCAGCCTTTGACATCA
BPIFB2-6:
ACCTGATGCCATGCATCGCACCATTCATATCACGAACACCCATTTATACTATATACTACCA CTAGCCAGCCTTTGACATCA
BPIFB2-7:
ACCTGATGCCATGCATCGCACGCACTAATATCCTTCATCCCTACTAATAACTCTTTTAACC CTAGCCAGCCTTTGACATCA
BPIFB2-8:
ACCTGATGCCATGCATCGCACACACTCATATTTATACACCAATATCATCTCACTCTATCTC CTAGCCAGCCTTTGACATCA
BPIFB2-9:
ACCTGATGCCATGCATCGCAAACCAAGAATGTCTTACGACATCTCGCCTACTATCCTATAT CTAGCCAGCCTTTGACATCA
BPIFB2-10:
ACCTGATGCCATGCATCGCACACATAACAATCTATTATTCCTCTATCCGCTCTTATATTCC CTAGCCAGCCTTTGACATCA
BPIFB2-11:
ACCTGATGCCATGCATCGCAAACCAGTCTACTCAACCGACCACCTCAATATCATTCTCATC CTAGCCAGCCTTTGACATCA
BPIFB2-12:
ACCTGATGCCATGCATCGCACTACCTATACAATACTTACTGTCTGCTTCTACTTCTATTAT CTAGCCAGCCTTTGACATCA
BPIFB2-13:
ACCTGATGCCATGCATCGCATATACTCGCAATCACTATATAAGACCACATAAATCACTTTA CTAGCCAGCCTTTGACATCA
BPIFB2-14:
ACCTGATGCCATGCATCGCACTAACCCAATATTATTAACCGCACCACTCACATAAATCAAG CTAGCCAGCCTTTGACATCA
BPIFB2-15:
ACCTGATGCCATGCATCGCATATCAACTCTCATATATTCTTCACATCCCTACCCTTGTTAC CTAGCCAGCCTTTGACATCA
BPIFB2-16:
ACCTGATGCCATGCATCGCAACAACATCTATCTACTTATCAACTTCAAAACTTTCATATTA CTAGCCAGCCTTTGACATCA
The performance measurement of embodiment 3 protein binding aptamer
Aptamer is taken respectively 2.0 μ g, digests lh with calf intestinal alkaline phosphatase (CIP) 37 DEG C, pure Change and reclaim dephosphorylized RNA；By T4 polynucleotide kinase labelling [γ-32P] ATP in dephosphorylized RNA molecule end.The radiolabeled aptamer of 10nmol respectively with the BPIFB2 of variable concentrations (1-200nM) Hatching 30min for 37 DEG C, each group reactant liquor filters through nitrocellulose filter, washs filter membrane, is dried filter membrane, liquid Dodging calculating instrument and measure the exit dose of residual on filter membrane, same sample is parallel does twice mensuration.Calculate each aptamer Dissociation constant with destination protein.Result is as follows:
Aptamer specificity analyses and stability analysis described in embodiment 4
It is respectively adopted human albumin, immune globulin, vibrio cholera VgrG3C albumen, escherichia coli Outer membrane protein A, COCH albumen, BPIFB2 albumen, carry out specific detection with 16 aptamers, pass through Binding tests finds, these aptamers do not combine with these albumen, and only protects with BPIFB2 protein binding Hold higher specificity.
By described aptamer, take 0.2ug, be respectively placed in the serum of room temperature, aqueous solution, place three weeks. Detected by RT-PCR, find its Stability Analysis of Structures of placement of three weeks, be not degraded.
The diagnosis of aptamer disease described in embodiment 5
Take the salivation thing of 11 oral cancer patients and 4 normal persons, use normal saline dilution, it is thus achieved that Target sample.
By 16 markd aptamers of coupling, secretions with 11 patients and 4 normal persons mixes respectively 30min, is separated by biotin, the content of quantitative analysis BPIFB2 therein albumen, is found by analysis, In 11 oral cancer patients, the content of BPIFB2 albumen dramatically increases, and has exceeded the threshold value of regulation.Reach mouth The diagnostic criteria of chamber cancer.As can be seen here, its diagnosis effect is preferable.
These are only the preferred embodiments of the present invention, be not limited to the present invention, for the skill of this area For art personnel, all any modification, equivalent substitution and improvement etc. done within the spirit and principles in the present invention, Should be included within the scope of the present invention.
Sequence table
＜ 110 ＞ Chen Bo
The test kit of a ＜ 120 ＞ oral cancer specific detection
〈160〉15
〈210〉1
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-1
ACCTGATGCCATGCATCGCATCACACGATCATCACACCGCTCCGCCTTCCAACTACCGCTC CTAGCCAGCCTTTGACATCA
〈210〉2
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-2
ACCTGATGCCATGCATCGCACACCTCCACCCTTCGCAACTACCTCTCTTCCTGTAACTATT CTAGCCAGCCTTTGACATCA
〈210〉3
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-3
ACCTGATGCCATGCATCGCATCTCATAACAAATCTTCATAATCTTCTATAACACTGTCAAT CTAGCCAGCCTTTGACATCA
〈210〉4
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-4
ACCTGATGCCATGCATCGCACATCTATATAGAATATATTCAATCCTCTCTCTTATATGCAT CTAGCCAGCCTTTGACATCA
〈210〉5
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-5
ACCTGATGCCATGCATCGCACTATCAACGACTCTCACGCAACGCTCTTCTTACTACATATA CTAGCCAGCCTTTGACATCA
〈210〉6
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-6
ACCTGATGCCATGCATCGCACCATTCATATCACGAACACCCATTTATACTATATACTACCA CTAGCCAGCCTTTGACATCA
〈210〉7
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-7
ACCTGATGCCATGCATCGCACGCACTAATATCCTTCATCCCTACTAATAACTCTTTTAACC CTAGCCAGCCTTTGACATCA
〈210〉8
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-8
ACCTGATGCCATGCATCGCACACACTCATATTTATACACCAATATCATCTCACTCTATCTC CTAGCCAGCCTTTGACATCA
〈210〉9
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-9
ACCTGATGCCATGCATCGCAAACCAAGAATGTCTTACGACATCTCGCCTACTATCCTATAT CTAGCCAGCCTTTGACATCA
〈210〉10
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-10
ACCTGATGCCATGCATCGCACACATAACAATCTATTATTCCTCTATCCGCTCTTATATTCC CTAGCCAGCCTTTGACATCA
〈210〉11
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-11
ACCTGATGCCATGCATCGCAAACCAGTCTACTCAACCGACCACCTCAATATCATTCTCATC CTAGCCAGCCTTTGACATCA
〈210〉12
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-12
ACCTGATGCCATGCATCGCACTACCTATACAATACTTACTGTCTGCTTCTACTTCTATTAT CTAGCCAGCCTTTGACATCA
〈210〉13
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-13
ACCTGATGCCATGCATCGCATATACTCGCAATCACTATATAAGACCACATAAATCACTTTA CTAGCCAGCCTTTGACATCA
〈210〉14
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-14
ACCTGATGCCATGCATCGCACTAACCCAATATTATTAACCGCACCACTCACATAAATCAAG CTAGCCAGCCTTTGACATCA
〈210〉15
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-15
ACCTGATGCCATGCATCGCATATCAACTCTCATATATTCTTCACATCCCTACCCTTGTTAC CTAGCCAGCCTTTGACATCA
〈210〉16
〈211〉 81
〈212〉DNA
＜ 213 ＞ artificial sequence
〈400〉BPIFB2-16
ACCTGATGCCATGCATCGCAACAACATCTATCTACTTATCAACTTCAAAACTTTCATATTA CTAGCCAGCCTTTGACATCA

Claims (3)

1., for a test kit for oral cancer detection, it contains can specificity and the protein bound aptamer of BPIFB2.
2. test kit as claimed in claim 1, it is characterised in that: described aptamer sequence is shown in SEQ ID No:13.
3. the method detecting oral cancer, it is characterised in that utilize the test kit described in any one of claim 1-2.
CN201610505457.7A 2015-11-15 2015-11-15 Kit for specific detection on oral cancer Pending CN105954519A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610505457.7A CN105954519A (en) 2015-11-15 2015-11-15 Kit for specific detection on oral cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510775735.6A CN105203763B (en) 2015-11-15 2015-11-15 A kind of test kit of oral cancer specific detection
CN201610505457.7A CN105954519A (en) 2015-11-15 2015-11-15 Kit for specific detection on oral cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201510775735.6A Division CN105203763B (en) 2015-11-15 2015-11-15 A kind of test kit of oral cancer specific detection

Publications (1)

Publication Number Publication Date
CN105954519A true CN105954519A (en) 2016-09-21

Family

ID=54951548

Family Applications (16)

Application Number Title Priority Date Filing Date
CN201610505458.1A Pending CN106053814A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610503478.5A Pending CN105891486A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610504451.8A Pending CN105891515A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610504452.2A Pending CN105891516A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610505457.7A Pending CN105954519A (en) 2015-11-15 2015-11-15 Kit for specific detection on oral cancer
CN201610503506.3A Pending CN105911295A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610505437.XA Pending CN105891518A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610503476.6A Pending CN105891513A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610505490.XA Pending CN105929163A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancers
CN201610504440.XA Pending CN105891514A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610504453.7A Pending CN105891517A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201510775735.6A Active CN105203763B (en) 2015-11-15 2015-11-15 A kind of test kit of oral cancer specific detection
CN201610505473.6A Pending CN105954520A (en) 2015-11-15 2015-11-15 Kit for specific detection on oral cancer
CN201610504455.6A Pending CN105891488A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610503507.8A Pending CN105911282A (en) 2015-11-15 2015-11-15 Kit for detecting oral cancer specificity
CN201610503479.XA Pending CN105891487A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN201610505458.1A Pending CN106053814A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610503478.5A Pending CN105891486A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610504451.8A Pending CN105891515A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610504452.2A Pending CN105891516A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer

Family Applications After (11)

Application Number Title Priority Date Filing Date
CN201610503506.3A Pending CN105911295A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610505437.XA Pending CN105891518A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610503476.6A Pending CN105891513A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610505490.XA Pending CN105929163A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancers
CN201610504440.XA Pending CN105891514A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610504453.7A Pending CN105891517A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201510775735.6A Active CN105203763B (en) 2015-11-15 2015-11-15 A kind of test kit of oral cancer specific detection
CN201610505473.6A Pending CN105954520A (en) 2015-11-15 2015-11-15 Kit for specific detection on oral cancer
CN201610504455.6A Pending CN105891488A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer
CN201610503507.8A Pending CN105911282A (en) 2015-11-15 2015-11-15 Kit for detecting oral cancer specificity
CN201610503479.XA Pending CN105891487A (en) 2015-11-15 2015-11-15 Kit for specific detection of oral cancer

Country Status (1)

Country Link
CN (16) CN106053814A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106093434A (en) * 2016-06-19 2016-11-09 曹帅 A kind of test kit for hepatocarcinoma detection
CN106018828A (en) * 2016-06-19 2016-10-12 曹帅 Reagent kit for detecting intestinal diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133770A2 (en) * 2010-04-21 2011-10-27 Board Of Regents Of The University Of Texas System Salivary protein markers for detection of breast cancer
CN104059982A (en) * 2014-07-04 2014-09-24 杨承刚 Oral squarmous cell carcinomas pathogenic gene BPIFB2 and application thereof
CN104830867A (en) * 2015-06-07 2015-08-12 杨洋 Aptamer capable of being specifically combined with DKK1 protein in cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014609A (en) * 2004-04-26 2007-08-08 阿切埃米克斯有限公司 Nucleic acid ligands to immunoglobuline e and their use as atopic disease therapeutics
US20090269744A1 (en) * 2005-10-28 2009-10-29 Exonhit Therapeutics Sa Cancer detection method
CA2700125A1 (en) * 2007-09-18 2009-03-26 Board Of Regents Of The University Of Texas System Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
WO2011099576A1 (en) * 2010-02-12 2011-08-18 国立大学法人 東京大学 Aptamer to fgf2 and use thereof
JP6591392B2 (en) * 2013-03-14 2019-10-16 ソマロジック, インコーポレイテッドSomaLogic, Inc. Aptamers that bind to IL-6 and their use in the treatment or diagnosis of IL-6 mediated conditions
CN104267185B (en) * 2014-09-12 2016-05-18 范飞舟 Detect the kit of tumour and the material of special identification 2-Acetamido-2-deoxy-D-glucose thereof
CN104818278A (en) * 2015-04-17 2015-08-05 刘红卫 Aptamer capable of being in specific binding to TS/MDEP protein in gastric cancer cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133770A2 (en) * 2010-04-21 2011-10-27 Board Of Regents Of The University Of Texas System Salivary protein markers for detection of breast cancer
CN104059982A (en) * 2014-07-04 2014-09-24 杨承刚 Oral squarmous cell carcinomas pathogenic gene BPIFB2 and application thereof
CN104830867A (en) * 2015-06-07 2015-08-12 杨洋 Aptamer capable of being specifically combined with DKK1 protein in cancer cells

Also Published As

Publication number Publication date
CN105911295A (en) 2016-08-31
CN105891517A (en) 2016-08-24
CN105203763B (en) 2017-01-04
CN105891487A (en) 2016-08-24
CN105891516A (en) 2016-08-24
CN105891513A (en) 2016-08-24
CN105891486A (en) 2016-08-24
CN105891514A (en) 2016-08-24
CN105954520A (en) 2016-09-21
CN105203763A (en) 2015-12-30
CN105891515A (en) 2016-08-24
CN105929163A (en) 2016-09-07
CN105891518A (en) 2016-08-24
CN105891488A (en) 2016-08-24
CN105911282A (en) 2016-08-31
CN106053814A (en) 2016-10-26

Similar Documents

Publication Publication Date Title
CN105203763B (en) A kind of test kit of oral cancer specific detection
CN105353126B (en) A kind of test kit of lip cancer specific detection
CN106018842A (en) Kit used for detecting ophthalmic diseases, and detection method thereof
CN105785007A (en) Kit for specific detection of endometrial cancer
CN105823894A (en) Kit for specific detection of endometrial cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160921

WD01 Invention patent application deemed withdrawn after publication